• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:54:46 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    SC 13G/A 1 ea135738-13ga1eitner_hoth.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1) 

     

    HOTH THERAPEUTICS, INC. 

    (Name of Issuer)

     

    COMMON STOCK 

    (Title of Class of Securities)

     

    44148G 10 5 

    (CUSIP Number)

     

    December 31, 2020 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     

     

     

     

     

    CUSIP No. 44148G 10 5 

      

    1

    NAME OF REPORTING PERSONS

    S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     
    Matthew Eitner

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐
    (b)
    ☐
    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     
     18,750(1)

    6

    SHARED VOTING POWER

     

    0 

    7

    SOLE DISPOSITIVE POWER

     
    18,750(1)

    8

    SHARED DISPOSITIVE POWER

     
    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    18,750(1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     
    0.14% (based on 13,439,229 shares outstanding as of January 7, 2021)

    12

    TYPE OF REPORTING PERSON

     

    IN 

     

     

    (1)Represents (i) 15,000 shares of common stock held by Mr. Eitner and (ii) 3,750 shares of common stock underlying warrants to purchase common stock held by Mr. Eitner.

     

    2

     

      

    Item 1(a).Name of Issuer:

     

    Hoth Therapeutics, Inc., a Nevada corporation (“Issuer”).

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    1 Rockefeller Plaza, Suite 1039, New York, NY 10020.

     

    Item 2(a).Name of Person Filing.

     

    The statement is filed on behalf of Matthew Eitner (the “Reporting Person”).

     

    Item 2(b).Address of Principal Business Office or, if None, Residence.

     

    521 Fifth Avenue, 12th Floor, New York, NY 10175

     

    Item 2(c).Citizenship.

     

    The Reporting Person is a citizen of the United States.

     

    Item 2(d).Title of Class of Securities.

     

    Common Stock, par value $0.0001.

     

      Item 2(e). CUSIP Number.

     

    44148G 10 5

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b), check whether the person filing is a

     

    (a) ☒ Broker or dealer registered under section 15 of the Act.

     

    Item 4.Ownership.

     

    (a) Amount beneficially owned: 18,750(1)

     

    (b) Percent of class 0.14% (based on 13, 439,229 shares common stock outstanding as of January 7, 2021)

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote: 18,750(1)

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 18,750(1)

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    (1)Represents (i) 15,000 shares of common stock held by Mr. Eitner and  (ii) 3,750 shares of common stock underlying warrants to purchase common stock held by Mr. Eitner.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    3

     

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Matthew Eitner
       
    Date: February 16, 2021 /s/ Matthew Eitner
      Matthew Eitner

     

     

    5

     

     

     

    Get the next $HOTH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    SEC Filings

    See more
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      6/24/25 4:05:40 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      6/20/25 8:00:13 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Hoth Therapeutics Inc.

      DEFA14A - Hoth Therapeutics, Inc. (0001711786) (Filer)

      6/16/25 4:10:27 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

      Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The n

      6/25/25 8:38:00 AM ET
      $HOTH
      $SILO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Apparel
      Consumer Discretionary
    • Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

      *Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and Silo Pharma, Inc. (NASDAQ:SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).

      6/25/25 8:27:00 AM ET
      $HOTH
      $SILO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Apparel
      Consumer Discretionary
    • Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

      Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities. Hoth Therapeutics will host a Key Opinion Leader (KOL) event on, at 3:30PM EST to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address EGFR inhibitor-induced skin toxicities in cancer patients. This event will feature insights from derm-oncology and dermatology specialists Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D., who will present interim results from the ongoing Phase 2 trial and discuss how HT-001 could redefine supportive care standards for oncology patients.  Access

      6/24/25 10:36:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/19/24 8:00:03 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Camarra Christopher Michael

      3 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      5/21/25 5:30:18 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and President Knie Robb

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:55 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Springer Graig

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:06 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

      Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc

      6/5/25 8:12:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

      NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

      1/31/22 8:17:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/24 2:47:32 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Hoth Therapeutics Inc.

      SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/23 12:55:35 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/8/23 6:07:04 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care